Generex says Oral-Lyn fits ADA/EASD guidance

The USA's Generex has suggested its Oral-Lyn oral insulin spray may address suggestions made in the consensus algorithm for type 2 diabetes treatment published by the American Diabetes Association and the European Association for the Study of Diabetes in the on-line journal Diabetes Care.

A joint panel of ADA and EASD experts updated the treatment recommendations for type 2 diabetes in a consensus statement that provides guidance to health care providers. Generex says that Oral-lyn, which delivers insulin into the mouth using the firm's RapidMist drug delivery device: is a fast, effective and pain-free alternative to prandial insulin injections; can augment the early intervention insulin therapy for diabetes contemplated by the algorithm; and assist in delaying the progression of the disease and the onset of its myriad complications. Oral-lyn is presently in global Phase III trials, with 260 subjects enrolled at 69 sites in seven countries.